Much of the public distrust stems from false information around messenger RNA (mRNA) vaccines for COVID-19, even though they ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Shares of Moderna (NASDAQ:MRNA) have been long forgotten about since its demand for COVID shots fell off a cliff more than three years ago. Indeed, if you axed Moderna off your watchlist after the ...

The approval of Moderna's Spikevax for kids at higher risk of contracting the disease continues the company's regulatory winning streak, which has also included nods for a next-gen COVID-19 vaccine ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

The approval comes amid regulatory upheaval under HHS head Robert F. Kennedy Jr., who has pushed for changes around mRNA ...

Fresh off of the heels of a shakeup at the CDC over vaccine recommendations, many Americans still question the necessity and ...

According to the CDC, there has been a decline in animal infections and no reports of human cases since February.

The U.S. Centers for Disease Control and Prevention has ended its emergency response to the H5N1 bird flu outbreak, a move ...

Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial.

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...